ACADIA Pharmaceuticals Inc.

20.60+0.1700+0.83%Vol 1.74M1Y Perf -51.63%
Apr 13th, 2021 16:00 DELAYED
BID20.51 ASK20.77
Open20.50 Previous Close20.43
Pre-Market- After-Market20.60
 - -  - -%
Target Price
30.47 
Analyst Rating
Strong Buy 1.43
Potential %
47.91 
Finscreener Ranking
★★★★+     56.33
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★     52.59
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★+     55.89
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap3.30B 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
1.24 
Earnings Date
6th May 2021

Today's Price Range

20.4220.90

52W Range

20.1258.72

5 Year PE Ratio Range

-18.80-14.00

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-2.97%
1 Month
-23.82%
3 Months
-62.17%
6 Months
-52.00%
1 Year
-51.63%
3 Years
8.99%
5 Years
-39.04%
10 Years
1 077.14%

TickerPriceChg.Chg.%
ACAD20.600.17000.83
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.312.40000.94
XOM55.710.21000.38
WFC39.79-0.9800-2.40
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Financial StrengthValueIndustryS&P 500US Markets
6.40
6.80
0.07
0.08
-
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
95.40
-64.90
-64.20
-406.10
-53.82
RevenueValueIndustryS&P 500US Markets
351.69M
2.20
41.78
367.03
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.48-0.4212.50
Q03 2020-0.38-0.54-42.11
Q02 2020-0.44-0.2738.64
Q01 2020-0.46-0.57-23.91
Q04 2019-0.37-0.348.11
Q03 2019-0.41-0.2929.27
Q02 2019-0.46-0.3817.39
Q01 2019-0.54-0.59-9.26
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.54-25.58Negative
6/2021 QR-0.43-22.86Negative
12/2021 FY-1.93-85.58Negative
12/2022 FY-0.51-132.48Negative
Next Report Date6th May 2021
Estimated EPS Next Report-0.54
Estimates Count10
EPS Growth Next 5 Years %-
Volume Overview
Volume1.74M
Shares Outstanding160.05M
Trades Count17.34K
Dollar Volume60.84M
Avg. Volume2.16M
Avg. Weekly Volume2.43M
Avg. Monthly Volume2.89M
Avg. Quarterly Volume2.33M

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) stock closed at 20.6 per share at the end of the most recent trading day (a 0.83% change compared to the prior day closing price) with a volume of 1.75M shares and market capitalization of 3.30B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 580 people. ACADIA Pharmaceuticals Inc. CEO is Stephen R. Davis.

The one-year performance of ACADIA Pharmaceuticals Inc. stock is -51.63%, while year-to-date (YTD) performance is -61.47%. ACAD stock has a five-year performance of -39.04%. Its 52-week range is between 20.12 and 58.72, which gives ACAD stock a 52-week price range ratio of 1.24%

ACADIA Pharmaceuticals Inc. currently has a PE ratio of -11.50, a price-to-book (PB) ratio of 5.28, a price-to-sale (PS) ratio of 9.30, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -34.44%, a ROC of -39.14% and a ROE of -40.57%. The company’s profit margin is -53.82%, its EBITDA margin is -64.20%, and its revenue ttm is $351.69 Million , which makes it $2.20 revenue per share.

Of the last four earnings reports from ACADIA Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.54 for the next earnings report. ACADIA Pharmaceuticals Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for ACADIA Pharmaceuticals Inc. is Strong Buy (1.43), with a target price of $30.47, which is +47.91% compared to the current price. The earnings rating for ACADIA Pharmaceuticals Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ACADIA Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ACADIA Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.09, ATR14 : 3.66, CCI20 : -99.86, Chaikin Money Flow : -0.32, MACD : -5.89, Money Flow Index : 29.20, ROC : -20.83, RSI : 19.69, STOCH (14,3) : 7.45, STOCH RSI : 0.02, UO : 26.21, Williams %R : -92.55), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ACADIA Pharmaceuticals Inc. in the last 12-months were: Austin D. Kim (Option Excercise at a value of $153 825), Austin D. Kim (Sold 12 607 shares of value $590 200 ), Elena Ridloff (Option Excercise at a value of $251 200), Elena Ridloff (Sold 14 117 shares of value $717 029 ), James M. Daly (Option Excercise at a value of $1 385 400), James M. Daly (Sold 52 500 shares of value $2 684 356 ), Michael J. Yang (Option Excercise at a value of $626 770), Michael J. Yang (Sold 31 118 shares of value $1 719 464 ), Srdjan Stankovic (Option Excercise at a value of $7 996 100), Srdjan Stankovic (Sold 365 802 shares of value $18 791 602 ), Stephen R. Davis (Option Excercise at a value of $3 929 999), Stephen R. Davis (Sold 227 409 shares of value $10 568 066 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
10 (71.43 %)
11 (73.33 %)
9 (64.29 %)
Moderate Buy
2 (14.29 %)
2 (13.33 %)
2 (14.29 %)
Hold
2 (14.29 %)
2 (13.33 %)
3 (21.43 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.43
Strong Buy
1.40
Moderate Buy
1.57

ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

CEO: Stephen R. Davis

Telephone: +1 858 558-2871

Address: 12830 El Camino Real, San Diego 92130, CA, US

Number of employees: 580

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

59%41%

Bearish Bullish

53%47%

Bearish Bullish

50%50%

News

Stocktwits